Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
نویسندگان
چکیده
OBJECTIVE To compare the diagnostic accuracy of CSF biomarkers and amyloid PET for diagnosing early-stage Alzheimer disease (AD). METHODS From the prospective, longitudinal BioFINDER study, we included 122 healthy elderly and 34 patients with mild cognitive impairment who developed AD dementia within 3 years (MCI-AD). β-Amyloid (Aβ) deposition in 9 brain regions was examined with [18F]-flutemetamol PET. CSF was analyzed with INNOTEST and EUROIMMUN ELISAs. The results were replicated in 146 controls and 64 patients with MCI-AD from the Alzheimer's Disease Neuroimaging Initiative study. RESULTS The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). The best PET measures performed similarly (AUC 0.92-0.93; anterior cingulate, posterior cingulate/precuneus, and global neocortical uptake). CSF Aβ42/t-tau and Aβ42/p-tau performed better than CSF Aβ42 and Aβ42/40 (AUC difference 0.03-0.12, p<0.05). Using nonoptimized cutoffs, CSF Aβ42/t-tau had the highest accuracy of all CSF/PET biomarkers (sensitivity 97%, specificity 83%). The combination of CSF and PET was not better than using either biomarker separately. CONCLUSIONS Amyloid PET and CSF biomarkers can identify early AD with high accuracy. There were no differences between the best CSF and PET measures and no improvement when combining them. Regional PET measures were not better than assessing the global Aβ deposition. The results were replicated in an independent cohort using another CSF assay and PET tracer. The choice between CSF and amyloid PET biomarkers for identifying early AD can be based on availability, costs, and doctor/patient preferences since both have equally high diagnostic accuracy. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that amyloid PET and CSF biomarkers identify early-stage AD equally accurately.
منابع مشابه
P 62: Markers of Neuroinflammation Related to Alzheimer\'s Disease Pathology in the Elderly
Alzheimer Disease (AD) is a neurodegenerative disorder and the most common form of dementia. Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. In vitro and animal studies have linked neuroinflammation to Alzheimer's disease (AD) pathology. Studies on marke...
متن کاملThe most valuable biomarkers of Alzheimer\'s disease: a review article
Alzheimer’s disease (AD) is the most popular type of dementia in elderly and is described by a progressive loss of cognitive capacity and severe neurodegeneration which typically begins with memory deficits. The major biomarkers of AD include total tau, phosphorylated-tau and 42 amino acid isoform of amyloid beta that reflect neurodegeneration and indicate the pathophysiological processes in AD...
متن کاملComparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
OBJECTIVE To compare PET imaging of tau pathology with CSF measurements (total tau [t-tau] and phosphorylated tau [p-tau]) in terms of diagnostic performance for Alzheimer disease (AD). METHODS We compared t-tau and p-tau and 18F-AV-1451 in 30 controls, 14 patients with prodromal AD, and 39 patients with Alzheimer dementia, recruited from the Swedish BioFINDER study. All patients with AD (pro...
متن کاملBiomarkers of Alzheimer disease: current and future applications to diagnostic criteria.
PURPOSE OF REVIEW This article reviews recent advances in imaging and fluid biomarkers for Alzheimer disease (AD) and their application to newly proposed diagnostic criteria across the continuum of AD. RECENT FINDINGS There have been remarkable developments in neuroimaging markers for AD over the past decade, most notably the advent of positron emission tomography (PET) amyloid imaging using ...
متن کاملNonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
IMPORTANCE Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in living patients and for the tracking of longitudinal changes, but the relation between biomarkers needs further study. OBJECTIVE To determine the association between CSF and PET amyloid biomarkers (cross-sectional and longi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 85 شماره
صفحات -
تاریخ انتشار 2015